Follow @ebcapital
Recent articles
Here's Why Arrowhead Pharmaceuticals Skyrocketed 12.7% Today
The clinical-stage developer of RNAi therapies is being added to the S&P 600 index.
Warren Buffett Is the World's Biggest Investor in These 5 Stocks
Berkshire Hathaway is the single largest shareholder of these well-known companies.
Top Stocks Warren Buffett Just Sold
Berkshire Hathaway sold these stocks last quarter, and that could mean you should sell them, too.
Who Had the Better Quarter: Gilead Sciences or Amgen?
Here's which one of these large-cap biotechs put up the best numbers in the first quarter.
Top Stocks Warren Buffett Just Bought
These were Berkshire Hathaway's biggest buys in the first quarter.
Here's Why Evolus Stock Tumbled 17.4% Today
The price slipped on news of a share offering by one of its biggest investors.
Marijuana Stocks: 5 Facts About Tilray's Quarterly Performance
Cannabis company Tilray's latest financial report includes plenty of pros and cons.
Aurora Cannabis: 8 Facts About Its Latest Quarter
Canada's second-biggest marijuana stock by revenue is growing rapidly, but losses continue.
Marijuana Stocks: 3 Key Takeaways From CannTrust’s Earnings
CannTrust's got big plans that could turn it into one of Canada's top pot stocks.
3 Stocks With Big News Coming at ASCO 2019
These cancer drug developers could report market-moving news soon.
Is It Finally Time to Buy Gilead Sciences?
Its been a tough few years for investors in this big-cap biotech, but signals are emerging that better days are ahead.
Guardant Health Takes Aim at Exact Sciences
A new study is planned that could someday reshape colon cancer screenings.
Marijuana Stocks: 7 Facts About Cronos Group's Quarterly Earnings
Here's what you should know about this fast-growing cannabis company following its latest quarterly financial results.
Were Invitae's Quarterly Results Really That Bad?
Sales slipped from the fourth quarter, but there's still a lot to like about this company.
3 Key Takeaways From Portola Pharmaceuticals' Quarterly Results
The company's still struggling to transition from clinical stage to commercial stage, but it's making progress.
Why Portola Pharmaceuticals Is Tumbling 14.5% Today
First-quarter financial results are failing to spark investor optimism on concerns over cash burn.
Here's the Bad News That Derailed Regeneron's Stock
This big-cap biotech has a problem or two on its hands.
Marijuana Stocks: 5 Facts You Need to Know About GW Pharmaceuticals Quarterly Results
GW Pharmaceuticals reported surging sales last quarter, but investors ought to be aware of a lot more than that.
Marijuana Medicine: GW Pharmaceuticals Market Opportunity Could Double
This drugmaker's cannabidiol formulation could become more widely used following positive phase 3 trial results in tuberous sclerosis complex.
Here's Why Esperion Therapeutics Shares Rocketed 11.5% Higher Today
The company is one step closer to securing an OK for its new cholesterol-busting drug.